Zhao Yue, Xie Yun, Jia Dianjun, Ma Chiluan, Wei Dongdong, Zhang Xiaoyu
Department II of Radiotherapy, Cangzhou Central Hospital Cangzhou, China.
Hebei Provincial Center for Disease Control and Prevention Hebei, China.
Am J Transl Res. 2021 Jun 15;13(6):7382-7387. eCollection 2021.
To analyze the value of gene polymorphisms in predicting the sensitivity of patients with locally advanced non-small-cell lung cancer (NSCLC) undergoing chemoradiotherapy.
Patients with locally advanced NSCLC undergoing chemoradiotherapy in our hospital from February 2017 to August 2019 were enrolled. X-ray repair cross complementing group 1 (XRCC1) gene polymorphisms were detected before chemoradiotherapy, and the correlation of XRCC1 gene polymorphisms with the sensitivity was analyzed.
There was no significant correlation of XRCC1 gene polymorphisms with age, gender, smoking status, pathological type, clinical stage and tumor size ( > 0.05). Among 98 patients with locally advanced NSCLC, 17 patients had complete response (CR), 25 patients had partial response (PR), 37 patients had stable disease (SD), and 19 patients had progressive disease (PD). A total of 42 patients were sensitive to chemoradiotherapy (CR + PR), and 56 patients were insensitive to treatment (SD + PD). The effect of XRCC1 gene polymorphisms on the efficacy of chemoradiotherapy was statistically significant ( < 0.05). In the codominant model GG vs. GA vs. AA, there was a significant difference (χ = 6.473, P = 0.039); The difference between AA and GA was significant (χ = 4.572, P = 0.032). The difference between AA and GG was significant (χ = 6.003, P = 0.014). There was no significant difference between GA and GG (χ = 0.015, P = 0.901). The rates of effective treatment for patients with XRCCI GG vs. GA vs. AA genotypes were 79.17%, 57.14%, and 47.37%, respectively. GG type was 1.38 times more effective than GA type, and GA type was 1.21 times more than AA type.
The Arg399Gln polymorphism of XRCC1 gene was significantly related to the sensitivity of patients with locally advanced NSCLC undergoing chemoradiotherapy. The sensitivity of patients carrying wild-type gene AA to chemoradiotherapy was significantly better than that of patients with GA and GG.
分析基因多态性在预测局部晚期非小细胞肺癌（NSCLC）患者放化疗敏感性中的价值。
纳入2017年2月至2019年8月在我院接受放化疗的局部晚期NSCLC患者。在放化疗前检测X射线修复交叉互补基因1（XRCC1）基因多态性，并分析XRCC1基因多态性与敏感性的相关性。
XRCC1基因多态性与年龄、性别、吸烟状况、病理类型、临床分期及肿瘤大小均无显著相关性（>0.05）。98例局部晚期NSCLC患者中，17例完全缓解（CR），25例部分缓解（PR），37例疾病稳定（SD），19例疾病进展（PD）。共有42例患者对放化疗敏感（CR+PR），56例患者对治疗不敏感（SD+PD）。XRCC1基因多态性对放化疗疗效的影响具有统计学意义（<0.05）。在共显性模型GG与GA与AA中，差异有统计学意义（χ=6.473，P=0.039）；AA与GA之间差异有统计学意义（χ=4.572，P=0.032）。AA与GG之间差异有统计学意义（χ=6.003，P=0.014）。GA与GG之间差异无统计学意义（χ=0.015，P=0.901）。XRCCI GG、GA、AA基因型患者的有效治疗率分别为79.17%、57.14%和47.37%。GG型疗效比GA型高1.38倍，GA型比AA型高1.21倍。
XRCC1基因的Arg399Gln多态性与局部晚期NSCLC患者放化疗的敏感性显著相关。携带野生型基因AA的患者对放化疗的敏感性显著优于携带GA和GG的患者。
